Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
15 hedge funds and large institutions have $52.8M invested in Clearside Biomedical in 2016 Q2 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$14.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$13.9M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$9.46M |
| 4 |
PA
Perceptive Advisors
New York
|
+$4.44M |
| 5 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$4.19M |
Top Sellers
CLSD Hedge Fund Activity: Q2 2016 in Review
15 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2016, worth a combined $52.8M.
Buyers outnumbered sellers: 15 funds opened new CLSD positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $14.6M.
- 15 institutional investors held Clearside Biomedical (CLSD) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $52.8M of Clearside Biomedical stock for Q2 2016.
- 15 funds opened new Clearside Biomedical positions in Q2 2016 and 0 closed out, a net change of +15 holders.
- The largest Clearside Biomedical buyer in Q2 2016 was Wellington Management Group, an estimated $14.6M added.
Based on aggregated 13F filings for Q2 2016.